Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
in vivo CAR-T
Biotech
Allogeneic CAR-T biotechs fight to escape 'nuclear winter'
As autologous CAR-T continues to improve and Big Pharma pumps big cash into next-gen approaches, is there room left at the table for allogeneic CAR-T?
Darren Incorvaia
Feb 11, 2026 11:00am
Lilly buys Orna in $2.4B deal to enter in vivo CAR-T arena
Feb 9, 2026 8:41am
In vivo gene editing biotech blossoms from Jennifer Doudna's lab
Nov 4, 2025 8:00am
Kite puts $1.64B on the line for Pregene's in vivo CAR-Ts
Oct 16, 2025 4:56pm
